Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study

Diabetes Care. 2023 May 1;46(5):e101-e102. doi: 10.2337/dc23-0083.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzhydryl Compounds / therapeutic use
  • Blood Glucose
  • Diabetes Mellitus, Type 1* / drug therapy
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Retrospective Studies

Substances

  • dapagliflozin
  • Hypoglycemic Agents
  • Benzhydryl Compounds
  • Blood Glucose